1.646.889.1200|info@lifescipublicrelations.com

Brainstorm Considering Right To Try For ALS Therapy

//Brainstorm Considering Right To Try For ALS Therapy

Brainstorm Considering Right To Try For ALS Therapy

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) is considering offering NurOwn to treat amyotrophic lateral sclerosis under the recently enacted federal right-to-try law, BrainStorm President and CEO Chaim Lebovits told BioCentury.

By | 2018-06-26T16:55:04-04:00 June 7th, 2018|News|Comments Off on Brainstorm Considering Right To Try For ALS Therapy

About the Author:

Related Posts

LifeSci Public Relations

LifeSci Public Relations LLC is a corporate communications and public relations firm helping clients engage their corporate audiences and achieve their business objectives via a broad array of traditional, social and digital media tools.